EA201590655A8 - Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений - Google Patents
Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушенийInfo
- Publication number
- EA201590655A8 EA201590655A8 EA201590655A EA201590655A EA201590655A8 EA 201590655 A8 EA201590655 A8 EA 201590655A8 EA 201590655 A EA201590655 A EA 201590655A EA 201590655 A EA201590655 A EA 201590655A EA 201590655 A8 EA201590655 A8 EA 201590655A8
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- combination
- lachinimode
- treatment
- neurodegenerative disorder
- patient suffering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Mechanical Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706695P | 2012-09-27 | 2012-09-27 | |
| US201361879004P | 2013-09-17 | 2013-09-17 | |
| PCT/US2013/062482 WO2014052933A1 (en) | 2012-09-27 | 2013-09-27 | Laquinimod and pridopidine for treating neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201590655A1 EA201590655A1 (ru) | 2015-12-30 |
| EA201590655A8 true EA201590655A8 (ru) | 2016-07-29 |
Family
ID=50339469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201590655A EA201590655A8 (ru) | 2012-09-27 | 2013-09-27 | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20150209346A1 (enExample) |
| EP (1) | EP2900330A4 (enExample) |
| CN (1) | CN104902958A (enExample) |
| AU (1) | AU2013323131A1 (enExample) |
| BR (1) | BR112015006623A2 (enExample) |
| CA (1) | CA2884781A1 (enExample) |
| EA (1) | EA201590655A8 (enExample) |
| HK (2) | HK1211525A1 (enExample) |
| IL (1) | IL237742A0 (enExample) |
| IN (1) | IN2015DN03219A (enExample) |
| MX (1) | MX2015003608A (enExample) |
| WO (1) | WO2014052933A1 (enExample) |
| ZA (1) | ZA201502600B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| PT2146961E (pt) * | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
| SG10201506761XA (en) | 2010-09-03 | 2015-10-29 | Teva Pharmaceuticals Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CA2847736A1 (en) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | A new polymorphic form of pridopidine hydrochloride |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX384234B (es) | 2013-06-21 | 2025-03-14 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para el tratamiento de enfermedad de huntington. |
| AU2014364447A1 (en) * | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3193870A4 (en) * | 2014-09-16 | 2018-04-25 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| EP4282479A3 (en) * | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| BR112019003732A2 (pt) | 2016-08-24 | 2020-02-18 | Prilenia Therapeutics Development Ltd. | Aplicação de pridopidina para tratamento de declínio funcional |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| DK3668509T3 (da) * | 2017-08-14 | 2023-02-20 | Prilenia Neurotherapeutics Ltd | Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin |
| CA3128250C (en) * | 2019-03-15 | 2024-01-16 | Michael Hayden | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| EP3982963B1 (en) * | 2019-06-12 | 2025-11-12 | Prilenia Neurotherapeutics Ltd. | Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101765428A (zh) * | 2007-06-18 | 2010-06-30 | A·卡尔森研究股份有限公司 | 多巴胺稳定剂的用途 |
| JP2012508768A (ja) * | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
| PL3064206T3 (pl) * | 2009-08-10 | 2020-02-28 | Active Biotech Ab | Leczenie choroby Huntingtona z zastosowaniem lakwinimodu |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| UA111959C2 (uk) * | 2010-12-07 | 2016-07-11 | Тева Фармасьютікл Індастріз Лтд. | Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом |
-
2013
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/en not_active Withdrawn
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/en not_active Ceased
- 2013-09-27 HK HK15112317.4A patent/HK1211525A1/xx unknown
- 2013-09-27 HK HK16102362.8A patent/HK1214553A1/zh unknown
- 2013-09-27 CA CA2884781A patent/CA2884781A1/en active Pending
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2884781A1 (en) | 2014-04-03 |
| BR112015006623A2 (pt) | 2017-07-04 |
| WO2014052933A1 (en) | 2014-04-03 |
| US20150209346A1 (en) | 2015-07-30 |
| EA201590655A1 (ru) | 2015-12-30 |
| EP2900330A4 (en) | 2016-05-25 |
| IL237742A0 (en) | 2015-05-31 |
| MX2015003608A (es) | 2015-06-05 |
| ZA201502600B (en) | 2016-06-29 |
| HK1214553A1 (zh) | 2016-07-29 |
| IN2015DN03219A (enExample) | 2015-10-02 |
| US20190117639A1 (en) | 2019-04-25 |
| US20180133209A1 (en) | 2018-05-17 |
| US20170319569A1 (en) | 2017-11-09 |
| AU2013323131A1 (en) | 2015-05-07 |
| CN104902958A (zh) | 2015-09-09 |
| HK1211525A1 (en) | 2016-05-27 |
| EP2900330A1 (en) | 2015-08-05 |
| US20180369228A1 (en) | 2018-12-27 |
| US20140088140A1 (en) | 2014-03-27 |
| US20180250285A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| CY1119420T1 (el) | Νεες θεραπευτικες προσεγγισεις για θεραπεια ασθενειας parkinson | |
| EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| BR112017003571A2 (pt) | terapia combinada | |
| MX365525B (es) | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| BR112015007095A2 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados | |
| MX2014014817A (es) | Compuestos para el tratamiento de inflamacion y dolor. | |
| MX2019004200A (es) | Terapia de combinacion. | |
| EA201401142A1 (ru) | Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3 | |
| WO2015073813A3 (en) | Treatment of diseases involving the hippo pathway |